Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | N/A | suspended | Aug 9, 2018 | Weill Medical College of Cornell University | Study is paused for interim analysis. | Efficacy / futility |
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | Phase 1 | withdrawn | Sep 17, 2021 | Sunshine Lake Pharma Co., Ltd. | Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled. | Enrollment / accrual |
| NCT04973007 | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of… | Phase 4 | terminated | Jul 22, 2021 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT04031469 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease | — | suspended | Jul 24, 2019 | ProgenaBiome | Administrative | Other (stated, no rule matched) |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06039202 | CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects… | Phase 2 | suspended | Sep 15, 2023 | Holy Stone Healthcare Co., Ltd | Strategy under discussion | Sponsor / business decision |
| NCT05041335 | Wet Heparinized Suction for Abdominal Cancer(EUS Heparin) | N/A | withdrawn | Sep 13, 2021 | H. Lee Moffitt Cancer Center and Research Institute | study no longer proceeding | Other (stated, no rule matched) |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT07720115 | Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal… | Phase 2 | withdrawn | Jul 22, 2026 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III… | N/A | terminated | Jul 5, 2023 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT06487377 | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… | Phase 1 | withdrawn | Jul 5, 2024 | Shanghai Pudong Hospital | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | Early Phase 1 | terminated | Jun 30, 2022 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co.,… | Sponsor / business decision |
| NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept,…(ResQ108B-PANC) | Phase 1 | withdrawn | Mar 23, 2026 | ImmunityBio, Inc. | The sponsor has changed the development plans which is not for safety reasons. | Safety / toxicity |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy… | Phase 2 | terminated | Mar 25, 2008 | Hoffmann-La Roche | not stated | Not stated |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT05494697 | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With… | Phase 2 | suspended | Aug 10, 2022 | AIM ImmunoTech Inc. | A business decision to place screening/enrollment on hold. Study redesign/amendment pending… | Enrollment / accrual |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated… | Phase 1 | terminated | Aug 11, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | company development strategy adjustment | Sponsor / business decision |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Jun 28, 2022 | T-ACE Medical Co., Ltd | T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug… | Other (stated, no rule matched) |
| NCT07629921 | Multimodal Al for Precision Diagnosis of Esophageal Cancer | — | terminated | Jun 5, 2026 | Shanghai Zhongshan Hospital | local ethics review | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to… | — | terminated | Aug 12, 2024 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04007640 | Early Screening of Pancreatic Lesions : Development of New Imaging Tools(PAIR-PANCREAS) | N/A | terminated | Jul 5, 2019 | Assistance Publique - Hôpitaux de Paris | Population difficult to recruit; number of enrolled patients sufficient for analyses. | Enrollment / accrual |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | withdrawn | Jan 24, 2024 | Fudan University | The study was withdrawn before participant enrollment because the research team decided not to… | Enrollment / accrual |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… | Phase 2 | suspended | Jul 9, 2025 | Hebei Medical University Fourth Hospital | Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug… | Drug supply |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | Phase 1 / Phase 2 | suspended | Jan 30, 2026 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03068403 | Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After…(RECT) | N/A | terminated | Mar 1, 2017 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials